FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590429908> ?p ?o ?g. }

• W2590429908 endingPage "324" @default.
• W2590429908 startingPage "324" @default.
• W2590429908 abstract "324 Background: No treatments (Txs) are currently recommended after discontinuation (DC) of sorafenib (SOR) for advanced HCC and there are limited reports of Tx patterns. This study assessed Tx patterns, resource use, and associated costs for a select cohort of patients (pts) from Spain. Methods: Via an internet-based chart review, 50 physicians provided clinical and resource use data for 5 de-identified pts each. Medical records were eligible if the pt was ≥18 years old, was diagnosed with advanced HCC, initiated first-line SOR after 2008, subsequently discontinued SOR, survived ≥2 months post-SOR DC, and had ≥6 months of follow-up data (or had died). Unit costs for healthcare resources were obtained from publicly-available sources and applied to the number of each resource type to obtain cost estimates. All analyses were descriptive in nature. Results: From September to October 2012, physicians provided data for 250 pts. Mean pt age was 61 years and 73% were male. At SOR initiation, 35% were Barcelona Cancer Liver Clinic stage B and 63% C. From SOR initiation to DC, 43% declined in Child-Pugh status. Following SOR DC, inpatient hospitalization was reported for 45% and emergency room visits for 49%. For those reported as having received supportive care (n=209), 73% received pain interventions, 42% nutritional support, 33% antiemetics, and 17% transfusions. 28% received anti-cancer Tx (chemotherapy, procedures). For all pts, hospitalization represented about half of total costs. For pts who received further anti-cancer Tx, chemotherapy and procedures represented about one-third of costs and hospitalization less than one-third. Total costs per pt are summarized (Table). Conclusions: Following sorafenib DC, most advanced HCC pts who we studied did not receive further anti-cancer Tx. Those who received further anti-cancer Tx had greater total healthcare costs, but these costs accrued over a longer period of time. [Table: see text]" @default.
• W2590429908 created "2017-03-03" @default.
• W2590429908 creator A5007312682 @default.
• W2590429908 creator A5023271820 @default.
• W2590429908 creator A5069970576 @default.
• W2590429908 creator A5077081728 @default.
• W2590429908 creator A5077829446 @default.
• W2590429908 date "2014-01-20" @default.
• W2590429908 modified "2023-10-16" @default.
• W2590429908 title "Economic burden of advanced hepatocellular carcinoma (HCC) in Spain among patients discontinuing first-line sorafenib." @default.
• W2590429908 doi "https://doi.org/10.1200/jco.2014.32.3_suppl.324" @default.
• W2590429908 hasPublicationYear "2014" @default.
• W2590429908 type Work @default.
• W2590429908 sameAs 2590429908 @default.
• W2590429908 citedByCount "0" @default.
• W2590429908 crossrefType "journal-article" @default.
• W2590429908 hasAuthorship W2590429908A5007312682 @default.
• W2590429908 hasAuthorship W2590429908A5023271820 @default.
• W2590429908 hasAuthorship W2590429908A5069970576 @default.
• W2590429908 hasAuthorship W2590429908A5077081728 @default.
• W2590429908 hasAuthorship W2590429908A5077829446 @default.
• W2590429908 hasConcept C118552586 @default.
• W2590429908 hasConcept C121608353 @default.
• W2590429908 hasConcept C126322002 @default.
• W2590429908 hasConcept C194828623 @default.
• W2590429908 hasConcept C195910791 @default.
• W2590429908 hasConcept C27415008 @default.
• W2590429908 hasConcept C2778019345 @default.
• W2590429908 hasConcept C2778695046 @default.
• W2590429908 hasConcept C2778715236 @default.
• W2590429908 hasConcept C71924100 @default.
• W2590429908 hasConcept C72563966 @default.
• W2590429908 hasConceptScore W2590429908C118552586 @default.
• W2590429908 hasConceptScore W2590429908C121608353 @default.
• W2590429908 hasConceptScore W2590429908C126322002 @default.
• W2590429908 hasConceptScore W2590429908C194828623 @default.
• W2590429908 hasConceptScore W2590429908C195910791 @default.
• W2590429908 hasConceptScore W2590429908C27415008 @default.
• W2590429908 hasConceptScore W2590429908C2778019345 @default.
• W2590429908 hasConceptScore W2590429908C2778695046 @default.
• W2590429908 hasConceptScore W2590429908C2778715236 @default.
• W2590429908 hasConceptScore W2590429908C71924100 @default.
• W2590429908 hasConceptScore W2590429908C72563966 @default.
• W2590429908 hasIssue "3_suppl" @default.
• W2590429908 hasLocation W25904299081 @default.
• W2590429908 hasOpenAccess W2590429908 @default.
• W2590429908 hasPrimaryLocation W25904299081 @default.
• W2590429908 hasRelatedWork W2017490810 @default.
• W2590429908 hasRelatedWork W2043470781 @default.
• W2590429908 hasRelatedWork W2066343552 @default.
• W2590429908 hasRelatedWork W2112861459 @default.
• W2590429908 hasRelatedWork W2318402467 @default.
• W2590429908 hasRelatedWork W2343849531 @default.
• W2590429908 hasRelatedWork W3004563436 @default.
• W2590429908 hasRelatedWork W3024283902 @default.
• W2590429908 hasRelatedWork W4308043948 @default.
• W2590429908 hasRelatedWork W66886536 @default.
• W2590429908 hasVolume "32" @default.
• W2590429908 isParatext "false" @default.
• W2590429908 isRetracted "false" @default.
• W2590429908 magId "2590429908" @default.
• W2590429908 workType "article" @default.